Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight specific results from the study, such as the significant reduction in LDL levels and corresponding decrease in coronary heart disease risk, particularly among black participants. The language used, such as 'game changer' and 'no brainer,' indicates an enthusiastic reception of the study's conclusions, emphasizing its relevance and perceived importance within the medical community.
The majority of discussions demonstrate a supportive stance toward the publication's findings, with many users echoing its conclusions about the protective effects of PCSK9 mutations.
There is a high level of curiosity regarding the implications of the study, with many users expressing eagerness to read and understand the research further.
Several discussions delve into complex topics, referencing specific study results and exploring the implications of LDL levels on heart disease, indicating a deep engagement with the article's content.
Participants generally perceive the findings to have significant implications for understanding heart disease risks, particularly in different populations, suggesting a strong belief in the study's impact.
And not even that, scientists studied low LDL cholesterol levels among different populations of different Genetics, And guess what they found? In some cases, the heart disease is lower, up to 10x times when their LDL cholesterol is low. https://t.co/q1h4x7JTad
yesterday's stunning MR results:
Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
@NutritionMadeS3 @LowCarbEyeDoc Note people with genetic LOF of PCSK9, which is a cause of lifelong hypobetalipoproteinemia, have no immune or other consequences and they do not get ASCVD. https://t.co/157TywRNE4
A6: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fewer cardiac events, even compared to those who were on the same treatment but for a shorter period of time. #KnowFH https://t.co/BHaiaYY0Hc https://t.co/9XgXH1KN6P
2/ We start in 2005-06: studies from Helen Hobbs, Jonathan Cohen & colleagues showing that people with *loss-of-function* mutations in PCSK9, which is made in the liver and secreted into the bloodstream, have ⬇️ blood LDL cholesterol (LDL-C) levels: https://t.co/QH5yrkTNos https://t.co/4BM4QWFobw
This video explains LDL cholesterol levels, exploring their physiological significance and the distinction between LDL and HDL. We discuss how specific genetic variations in the PCSK9 gene can lead to reduced LDL…
Why do some individuals with high cholesterol avoid heart attacks while others with normal levels do not? This video explores the impact of DNA variations in the PCSK9 gene on LDL cholesterol levels and coronary heart…
Consuming whole apples or apple pomace can lower LDL cholesterol levels, whereas clear apple juice may increase it, indicating different effects on blood lipids. Fiber in apples, such as pectin, plays a key role in…
Nutrition in Five Minutes explores scientific evidence on how to lead healthier lives through nutrition. This video investigates how LDL cholesterol levels relate to cardiovascular mortality, revealing the importance of…
@MikeCarrato @newstart_2024 Great study: https://t.co/xlpx4gz2P9
RT @DrSamuelBHume: https://t.co/UvFe6hMI9o
https://t.co/UvFe6hMI9o
@pylondusk @marolda007 @MasalaFry69 @annavwellness @Dearme2_ 1/ Assuming [Cohen JC (2006)]. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. Thank you, I'll read it. I see some faults based on your introduction alone. (cont)
@Nurlygayanov @AnonAno5829114 https://t.co/TUwJUPW9Wn https://t.co/uB1CdFNbSK (just to clarify: I dont think pushing to very low levels is needed in many people, mainly those at v. high risk. its always about the risk/benefit)
@astupple @ernsterlanson https://t.co/hdCmqijjNC
@RHd1983 @realDaveFeldman PCSK9 LOF certainly leads to low lifetime risk of coronary heart disease. But that has been known for around 20 years. https://t.co/ly9YjOOOhX
APOL1 and kidney disease in Black individuals-https://t.co/rgyFMsHg1d PCSK9 and CHD in Black and White individuals-https://t.co/ZOL3Vmtpt7 more recently, FBN1 and height in Peruvians-https://t.co/2L9AqrrmYt tons of other examples..
A3: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fewer cardiac events, even compared to those who were on the same treatment but for a shorter period of time. #KnowFH https://t.co/BHaiaYY0Hc
@SergiEscanes @shameermulji LDL is measured and there is a control in those studies.. here’s one example https://t.co/31c4gnaeei
@Drlipid @DrMichaelShapir @Tellit007 @bmorecardiology @nationallipid ...was only 100 mg/dL in these patients, which isn't quite "hypobetalipoproteinemia" territory as I understand it (at least on average). Thanks. https://t.co/hRyVwtPujF https://t.co/SPHGcbFcLo
@Marion436842126 @FrontRowRx @ElieJarrougeMD I'm afraid I don't see the relevance of the quoted tweet to the study we're discussing here, which was looking at those with genetic variations in PCSK9, not a trial of PCSK9 inhibitors which is what the quoted tweet refers to. https://t.co/DXE5J31yQo
@thelowcarb_rd @Drlipid But this is hardly an obscure study so you may well be aware of it already! https://t.co/DXE5J31yQo
@realDaveFeldman @JohnKastelein https://t.co/ndYnot5wt1
RT @TheFHFoundation: A6: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fe…
RT @TheFHFoundation: A6: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fe…
RT @TheFHFoundation: A6: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fe…
A6: Results from a clinical trial of PCSK9 inhibitor evolocumab showed those who got their LDL lower for longer had fewer cardiac events, even compared to those who were on the same treatment but for a shorter period of time. #KnowFH https://t.co/BHaiaYY0Hc https://t.co/9XgXH1KN6P
@DoctorJLam @SebPillon I think the observational genetic data can help with education. Individuals with inherited PCSK9 loss of function have a hugely reduced risk of CVD. Up to 88% for some pops. So inhibiting the gene’s expression for the rest of us seems a no brainer. https://t.co/hKuNxxdXqI
@MohammedAlo @TuckerGoodrich @realDaveFeldman @PeterJAnderson_ @Drlipid @LowCarbEyeDoc @rcextremebike @AsarCadyn @SanDiegoJoey @lipo_fan Furthermore: “these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03)” https://t.co/mYE35wFriE
@rcextremebike @MohammedAlo @realDaveFeldman @PeterJAnderson_ @Drlipid @LowCarbEyeDoc @AsarCadyn @SanDiegoJoey It's black and white patients: https://t.co/bVUq9q9Ian https://t.co/eMPhIRlrKm
@efb_1 @OliveChirper PCSK9 inhibitors basically turn you into a PCSK9 knockout, which over a lifetime eliminates most of the risk of coronary heart disease. https://t.co/oILzNo950N
@REV_Insulin_Res @TheBhupiThakur https://t.co/k9zFt1XGvK https://t.co/vfbXkwZIKN we have studies in which folk are randomised genetically to lower levels of LDL & therefore lower risk of CVD
RT @michaelhoffman: GW: Heterozygous loss of function in PCSK9 → low plasma LDL and protection from coronary heart disease. By @lab_hobbs #…
GW: Heterozygous loss of function in PCSK9 → low plasma LDL and protection from coronary heart disease. By @lab_hobbs #BioNetAB2023 https://t.co/L8eudsALo9 https://t.co/bkgEFMYRzk
और सिर्फ यही नहीं , वैज्ञानिको ने अलग अलग आनुवंशिक जनसंख्या में कम एलडीएल कोलेस्ट्रोल लेवल के बारे में अध्ययन किया , और अंदाजा लगाइए कि उन्हें क्या मिला ? कुछ मामलों में हृदय रोग बहुत कम है , 10× कम है ! एलडीएल कोलेस्ट्रॉल लेवल कम होने के कारण । https://t.co/q1h4x7JTad
And not even that, scientists studied low LDL cholesterol levels among different populations of different Genetics, And guess what they found? In some cases, the heart disease is lower, up to 10x times when their LDL cholesterol is low. https://t.co/q1h4x7JTad
RT @lipo_fan: Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. https://t.co/opqw5X2iRz
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. https://t.co/opqw5X2iRz
@diego06566802 https://t.co/9HJt8rodFQ https://t.co/PLC3jWjQMk https://t.co/pERdrTIQ7n https://t.co/AijefI0mF9 https://t.co/J5KsbDtoYM https://t.co/fnmNY6niAi https://t.co/UIeOO69gVT https://t.co/J5KsbDtoYM
@diego06566802 https://t.co/9HJt8rodFQ https://t.co/PLC3jWjQMk https://t.co/pERdrTIQ7n https://t.co/AijefI0mF9 https://t.co/J5KsbDtoYM https://t.co/fnmNY6niAi https://t.co/UIeOO69gVT https://t.co/J5KsbDtoYM
@realDaveFeldman https://t.co/9HJt8rodFQ https://t.co/PLC3jWjQMk https://t.co/pERdrTIQ7n https://t.co/AijefI0mF9 https://t.co/J5KsbDtoYM https://t.co/fnmNY6niAi https://t.co/UIeOO69gVT https://t.co/J5KsbDtoYM
@Andysmalls13 @ZackStrength This is not a meta-analysis. This is a very poor, low level literature review. https://t.co/FRKgRhaysg https://t.co/D3gMt343Cn https://t.co/D3JQgU7fmS https://t.co/zr0tYpjGi9 https://t.co/zPFKqugLvj https://t.co/giNVjzzZD9 https://t.co/ds4XZXrkWv https://t.co/BlvjOiutJQ
RT @Drlipid: @NutritionMadeS3 @LowCarbEyeDoc Note people with genetic LOF of PCSK9, which is a cause of lifelong hypobetalipoproteinemia, h…
@NutritionMadeS3 @LowCarbEyeDoc Note people with genetic LOF of PCSK9, which is a cause of lifelong hypobetalipoproteinemia, have no immune or other consequences and they do not get ASCVD. https://t.co/157TywRNE4
Ceux qui naissent avec une mutation qui leur confère un LDL très bas ont un risque beaucoup plus faible de maladies cardiovasculaires même s'ils ont un mode de vie parfaitement normal (c-à-d mauvais) : https://t.co/m8GYdn9lA1 ⬇️ https://t.co/2ZXL26xp8q
@thoroughlyconf1 @ScepticalDoctor @skepcard Interested in your point of view contrary to mine. With respect. What reading do you give to this paper for example? https://t.co/opqw5X2iRz
@BowTiedLoon @BowTiedOx The natural variant of pcsk9 loss of function, for example https://t.co/MsbrRKL54Z
RT @Drlipid: @KyleMcnease @PeterAttiaMD Regarding PCSK9i and cognitive impairment - see https://t.co/8q4l8zp69H Also realize that people wi…
@KyleMcnease @PeterAttiaMD Regarding PCSK9i and cognitive impairment - see https://t.co/8q4l8zp69H Also realize that people with lifelong LOF of PCSK9 have reduced ASCVD & no cognitive issues: see https://t.co/157TywAcMw
@zanesmith331 @SBakerMD Quite the contrary actually… https://t.co/SLi2VfPto0 https://t.co/b0nSaufOeR https://t.co/yDdh4uvA42 https://t.co/LEUJpxnMEq https://t.co/M31sDhBRqy
RT @deep__wreck: @67MajorMinor NEJM 2006、米国→PCSK9ミスセンスミューテーション保有者、黒人ではLDL28%↓/冠動脈疾患88%↓、白人でLDL15%↓/冠動脈疾患47%↓ https://t.co/mo00zh8l4n
@67MajorMinor NEJM 2006、米国→PCSK9ミスセンスミューテーション保有者、黒人ではLDL28%↓/冠動脈疾患88%↓、白人でLDL15%↓/冠動脈疾患47%↓ https://t.co/mo00zh8l4n
RT @RalphSmorra: @CountyAurelius @SalvatoreMRighi Thats not a survey, but an interventional trial. Normally, you cant control what people e…
@CountyAurelius @SalvatoreMRighi Thats not a survey, but an interventional trial. Normally, you cant control what people eat long term, just ask &/or recommend. That study had to be done in a mental hospital to do so. In a natural experiment, ppl w genetically lower LDL have 88% lower CVD.https://t.co/hhLOE900Wi
@LDLSkeptic @maya__42 @KenDBerryMD @ProfTimNoakes @DrAseemMalhotra @FructoseNo @BelindaFettke @eatmostlyfatali Also tell me why people who are born with variations in pcsk9 which causes lower levels of LDL than the general population have they also just happen to also have way lower Coronary events compared to normal: https://t.co/0719ePjfyk
Ridurre il colesterolo LDL riduce il rischio di malattia coronarica (infarto, morte o angioplastica): - riduzione LDL 15% riduce del 47% il rischio di malattia coronarica ; - riduzione LDL del 28% riduce dell’88% il rischio di malattia coronarica . https://t.co/HdnLAsfJzJ
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @skathire: Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
Cholesterol treatment trialists: https://t.co/bhYct6uqt3 PCSK9 loss of function: https://t.co/uPjTLzxNEx
RT @kiranmusunuru: 2/ We start in 2005-06: studies from Helen Hobbs, Jonathan Cohen & colleagues showing that people with *loss-of-functio…
RT @kiranmusunuru: 2/ We start in 2005-06: studies from Helen Hobbs, Jonathan Cohen & colleagues showing that people with *loss-of-functio…
RT @kiranmusunuru: 2/ We start in 2005-06: studies from Helen Hobbs, Jonathan Cohen & colleagues showing that people with *loss-of-functio…
2/ We start in 2005-06: studies from Helen Hobbs, Jonathan Cohen & colleagues showing that people with *loss-of-function* mutations in PCSK9, which is made in the liver and secreted into the bloodstream, have ⬇️ blood LDL cholesterol (LDL-C) levels: https://t.co/QH5yrkTNos https://t.co/4BM4QWFobw
@thoroughlyconf1 @NathanEqualsOne @dylanarmbruste3 @mosca_matthew https://t.co/KGOs84T92A
RT @naifalmontashir: عام ٢٠٠٦، وجد طبيب عائلات أفريقية معمره وبالكاد يوجد لديها تاريخ مرضى بأمراض القلب التاجية ولديهم إنخفاض حاد في الكولي…
@Gearoidmuar @Alecsplaining We see massive reductions in CVD risk with moderately lower lifelong exposure to LDL (88% reduced risk in this example). This is definitely something that needs to be addressed. The earlier the better, and the lower the better https://t.co/cjq3RaxSis
@bubblehslol @nmplol you're missing a step there mate. High LDL cholesterol is STRONGLY correlated with heart disease: https://t.co/wUHEwoxjyy https://t.co/YOwEZxG2KG https://t.co/hL6aZKjz3u just because saturated fat diets don't always lead to high cholesterol, high cholesterol often leads to HD
@healthcoachkait PCSK9: https://t.co/0SraRP9pc1 LDL: https://t.co/qztSPi9G8S Mortality: https://t.co/nFUyaywexL Inflammation: https://t.co/m1tyDqFDS4 LDL: https://t.co/8fF6aOaa8n CHD: https://t.co/RK3aRtxGQj Children/LDL: https://t.co/HiaWYpH9TB
@DaveKeto @DaleBrubaker @LDLSkeptic @FatEmperor @bschermd @DietDoctor The problem with LMHR project is an issue of duration. Standard lipid hypothesis is focused on lifelong ApoB exposure Genetic variants that lower ApoB show dramatic reductions in cv events https://t.co/qOg0biR304
@ShariqShamimMD @DaveKeto @ThromBean @FatEmperor https://t.co/XpRFrLnkHd interestingly this study showed a near absence of heart disease in black subjects but white subjects still had 6% incidence compared to 11% in those without a PCSK9 mutation. So white subjects still far from eliminating heart disease
RT @NutritionMadeS3: yesterday's stunning MR results:
RT @NutritionMadeS3: yesterday's stunning MR results:
RT @NutritionMadeS3: yesterday's stunning MR results:
yesterday's stunning MR results:
@twitevit mendelian randomization = looking at people who carry mutations giving them low or high LDL it's extremely powerful evidence there are many of these showing low LDL=lower risk of CAD, high LDL=higher risk https://t.co/TUwJUPVC6P
@cureffi @leonidkruglyak @hilsomartin @konradjk @dgmacarthur @SchreiberStuart @dalygene @Jalfoldi @nickywhiffin Respectfully, humans tolerate a PCSK9 KO just fine: https://t.co/kijIuLLWSh and https://t.co/YT8nA3F4vf (perhaps I do not understand your point, in which case, apologies)